10-Q: TherapeuticsMD Reports Q3 2024 Results, Revenue Increases Amidst Transition to Royalty Model

TherapeuticsMD's third quarter 2024 results show increased license revenue and reduced operating expenses as the company continues its transition to a pharmaceutical royalty business.

Summary

• TherapeuticsMD reported a net loss of $609 thousand for the third quarter of 2024, an improvement from the $3.378 million loss in the same period of 2023.
• License and service revenue increased to $547 thousand in Q3 2024, compared to a negative $53 thousand in Q3 2023, due to product sales adjustments reported by licensees in the prior year.
• Operating expenses decreased by 18.3% to $1.406 million in Q3 2024, driven by cost reductions following the company's shift to a royalty-based model.
• For the first nine months of 2024, the net loss was $2.433 million, compared to a net loss of $9.395 million for the same period in 2023.
• License revenue for the first nine months of 2024 was $1.094 million, up from $800 thousand in the same period of 2023.
• The company recognized an impairment loss of $1.261 million related to abandoned patents and applications in the second quarter of 2024.
• TherapeuticsMD's primary revenue source is now royalties from licensed products, with Mayne Pharma, Theramex, and Knight being the main contributors.
• The company is managing ongoing disputes with Mayne Pharma regarding net working capital adjustments from the 2022 transaction.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to improved financial results and the transition to a royalty model, but concerns remain about the company's ability to continue as a going concern and the ongoing dispute with Mayne Pharma.

Positives

• The company's transition to a royalty-based model has led to increased license revenue and reduced operating expenses.
• The net loss has significantly decreased compared to the previous year, indicating improved financial performance.
• The company has secured royalty agreements with multiple partners, providing a diversified revenue stream.
• TherapeuticsMD has successfully reduced its selling, general, and administrative expenses by 17.6% in Q3 2024.
• The company has a long-term royalty receivable of $16.610 million, providing future revenue visibility.

Negatives

• The company is still operating at a loss, with a net loss of $609 thousand in Q3 2024.
• There is an ongoing dispute with Mayne Pharma regarding net working capital adjustments, creating uncertainty.
• The company recognized a $1.261 million impairment loss on long-lived assets, impacting profitability.
• The company's ability to continue as a going concern is uncertain, requiring potential capital raises.
• The company has a limited number of employees and relies heavily on external consultants.

Risks

• The company's ability to continue as a going concern is uncertain, dependent on securing additional financing.
• The ongoing dispute with Mayne Pharma over net working capital adjustments could have a material impact on the company's financials.
• The company's reliance on a limited number of licensees for revenue creates concentration risk.
• The company's success is dependent on the commercial performance of its licensees.
• The company faces potential risks related to supply chain issues and third-party contract manufacturers.

Future Outlook

The company may need to raise additional capital to fund operations until it becomes cash flow positive, and is exploring various equity and debt financing options. The company's future performance is dependent on the sales of licensed products by its partners and the resolution of the net working capital dispute with Mayne Pharma.

Management Comments

• Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.
• Management believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable.

Industry Context

The shift to a royalty-based model is a strategic move for TherapeuticsMD, aligning with a trend of pharmaceutical companies focusing on core competencies and licensing out assets. This model allows the company to leverage the commercial capabilities of its partners while reducing its own operational costs. The company's success will depend on the market performance of its licensed products and the effectiveness of its partnerships.

Comparison to Industry Standards

• TherapeuticsMD's transition to a royalty model is similar to other pharmaceutical companies that have divested commercial operations to focus on research and development or intellectual property management.
• The company's revenue is now primarily dependent on royalty payments, which is a common practice in the pharmaceutical industry, especially for companies with a strong patent portfolio.
• The company's operating expenses have decreased significantly, which is a positive sign compared to companies that maintain large commercial operations.
• The ongoing dispute with Mayne Pharma is a risk that is not uncommon in pharmaceutical licensing agreements, where disagreements over financial terms can arise.
• The company's need for additional capital is a common challenge for smaller pharmaceutical companies, especially those in transition.

Management Changes

Legal Proceedings

• The company is involved in patent litigation with Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc. regarding generic versions of IMVEXXY.
• Mayne Pharma is responsible for all enforcement of the company's patents, including the costs of litigation.

Related Party Transactions

• Justin Roberts, a director of the company, is a Partner of Rubric Capital Management LP.
• The company has entered into subscription agreements with Rubric Capital Management LP, resulting in the sale of common stock.
• The company redeemed all outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric Capital Management LP.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises.
• Employees are limited to one full-time employee and external consultants.
• Customers are now served by the company's licensees.
• Suppliers are impacted by the company's transition to a royalty model.
• Creditors are impacted by the company's financial performance and potential need for additional financing.

Next Steps

• The company will continue to monitor the net working capital dispute with Mayne Pharma.
• The company will explore various equity and debt financing options to address its capital needs.
• The company will continue to manage its relationships with current partners and assist with financial, legal, and regulatory matters.

Key Dates

Keywords

royalty, license, pharmaceutical, TherapeuticsMD, Mayne Pharma, IMVEXXY, BIJUVA, ANNOVERA, financial results, net loss, operating expenses, revenue, discontinued operations, patent impairment